Overexpression of the microRNA miR-433 promotes resistance to paclitaxel through the induction of cellular senescence in ovarian cancer cells

Cancer Medicine

Volumn 4, Issue 5, 2015, Pages 745-758

  Weiner Gorzel, Karolina ^a   Dempsey, Eugene ^a   Milewska, Malgorzata ^a   Mcgoldrick, Aloysius ^a   Toh, Valerie ^a   Walsh, Aoibheann ^a   Lindsay, Sinead ^a   Gubbins, Luke ^a   Cannon, Aoife ^b   Sharpe, Daniel ^c   O'Sullivan, Jacintha ^b   Murphy, Madeline ^a   Madden, Stephen F ^d   Kell, Malcolm ^e   Mccann, Amanda ^a   Furlong, Fiona ^c  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b ST JAMES S HOSPITAL   (Ireland)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^d DUBLIN CITY UNIVERSITY   (Ireland)

^e MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

CDK6; Chemoresistance; MiR 433; Ovarian cancer; Senescence

Indexed keywords

BETA GALACTOSIDASE; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN E; HISTONE DEACETYLASE 6; INTERLEUKIN 6; INTERLEUKIN 8; MICRORNA; MICRORNA 433; MITOGEN ACTIVATED PROTEIN KINASE 14; PACLITAXEL; PROTEIN MAD2; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F3; UNCLASSIFIED DRUG; MESSENGER RNA; MIRN433 MICRORNA, HUMAN;

APOPTOSIS; ARTICLE; CELL AGING; CELL CYCLE G1 PHASE; CELL STRUCTURE; CELL SURVIVAL; CELL VIABILITY; CHEMOSENSITIVITY; COMPUTER MODEL; CONTROLLED STUDY; CULTURE MEDIUM; DOWN REGULATION; ENZYME ACTIVITY; EXOSOME; GENE OVEREXPRESSION; GENE TARGETING; INTRACELLULAR SIGNALING; MEMBRANE MICROPARTICLE; OVARIAN CANCER CELL LINE; OVARY CANCER; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SENESCENCE; STABLE EXPRESSION; TUMOR MICROENVIRONMENT; UPREGULATION; BIOLOGY; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; HUMAN; OVARY TUMOR; RNA INTERFERENCE; TUMOR CELL LINE;

APOPTOSIS; CELL AGING; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; CYCLIN-DEPENDENT KINASE 6; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; MICRORNAS; OVARIAN NEOPLASMS; PACLITAXEL; RNA INTERFERENCE; RNA, MESSENGER; TUMOR MICROENVIRONMENT;

EID: 84991349195     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.409     Document Type: Article

References (48)

1. Vaughan, S., J. I. Coward, R. C. Bast Jr., A. Berchuck, J. S. Berek, J. D. Brenton, et al. 2011. Rethinking ovarian cancer: recommendations for improving outcomes. Nat. Rev. Cancer 11:719-725.
2. Berns, E. M., and D. D. Bowtell . 2012. The changing view of high-grade serous ovarian cancer. Cancer Res. 72:2701-2704.
3. Cho, K. R., and IeM Shih . 2009. Ovarian cancer. Annu. Rev. Pathol. 4:287-313.
4. Kanakkanthara, A., P. H. Teesdale-Spittle, and J. H. Miller . 2013. Cytoskeletal alterations that confer resistance to anti-tubulin chemotherapeutics. Anticancer Agents Med. Chem. 13:147-158.
5. Furlong, F., P. Fitzpatrick, S. O'Toole, S. Phelan, B. McGrogan, A. Maguire, et al. 2012. Low MAD2 expression levels associate with reduced progression free survival in patients with high-grade serous epithelial ovarian cancer. J. Pathol. 226:746-755.
6. Zhang, Y., and J. M. Yang . 2011. The impact of cellular senescence in cancer therapy: is it true or not? Acta Pharmacol. Sin. 32:1199-1207.
7. Rodier, F., and J. Campisi . 2011. Four faces of cellular senescence. J. Cell Biol. 192:547-556.
8. Campisi, J. 2013. Aging, cellular senescence, and cancer. Annu. Rev. Physiol. 75:685-705.
9. Munro, S., S. M. Carr, and N. B. La Thangue . 2012. Diversity within the pRb pathway: is there a code of conduct? Oncogene 31:4343-4352.
10. Konstantinopoulos, P. A., and U. A. Matulonis . 2013. Current status and evolution of preclinical drug development models of epithelial ovarian cancer. Front. Oncol. 3:296.
11. Kasinski, A. L., and F. J. Slack . 2011. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat. Rev. Cancer 11:849-864.
12. Ueda, T., S. Volinia, H. Okumura, M. Shimizu, C. Taccioli, S. Rossi, et al. 2010. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol. 11:136-146.
13. Lin, X., K. L. Rice, M. Buzzai, E. Hexner, F. F. Costa, O. Kilpivaara, et al. 2012. miR-433 is aberrantly expressed in myeloproliferative neoplasms and suppresses hematopoietic cell growth and differentiation. Leukemia 27:344-352.
14. Del Vescovo, V., T. Meier, A. Inga, M. A. Denti, and J. Borlak . 2013. A cross-platform comparison of affymetrix and Agilent microarrays reveals discordant miRNA expression in lung tumors of c-Raf transgenic mice. PLoS One 8:e78870.
15. Simon, D., B. Laloo, M. Barillot, T. Barnetche, C. Blanchard, C. Rooryck, et al. 2010. A mutation in the 3'-UTR of the HDAC6 gene abolishing the post-transcriptional regulation mediated by hsa-miR-433 is linked to a new form of dominant X-linked chondrodysplasia. Hum. Mol. Genet. 19:2015-2027.
16. Gotanda, K., T. Hirota, N. Matsumoto, and I. Ieiri . 2013. MicroRNA-433 negatively regulates the expression of thymidylate synthase (TYMS) responsible for 5-fluorouracil sensitivity in HeLa cells. BMC Cancer 13:369.
17. Yang, Z., H. Tsuchiya, Y. Zhang, M. E. Hartnett, and L. Wang . 2013. The microRNA-433 inhibits liver cancer cell migration by repressing the protein expression and function of cAMP response element binding protein. J. Biol. Chem. 288:28893-28899.
18. Snyder, C. M., A. L. Rice, N. L. Estrella, A. Held, S. C. Kandarian, and F. J. Naya . 2013. MEF2A regulates the Gtl2-Dio3 microRNA mega-cluster to modulate WNT signaling in skeletal muscle regeneration. Development 140:31-42.
19. Luo, H., H. Zhang, Z. Zhang, X. Zhang, B. Ning, J. Guo, et al. 2009. Down-regulated miR-9 and miR-433 in human gastric carcinoma. J. Exp. Clin. Cancer Res. 28:82.
20. Guo, L. H., H. Li, F. Wang, J. Yu, and J. S. He . 2013. The tumor suppressor roles of miR-433 and miR-127 in gastric cancer. Int. J. Mol. Sci. 14:14171-14184.
21. Prencipe, M., P. Fitzpatrick, S. Gorman, M. Tosetto, R. Klinger, F. Furlong, et al. 2009. Cellular senescence induced by aberrant MAD2 levels impacts on paclitaxel responsiveness in vitro. Br. J. Cancer 101:1900-1908.
22. Paraskevopoulou, M. D., G. Georgakilas, N. Kostoulas, I. S. Vlachos, T. Vergoulis, M. Reczko, et al. 2013. DIANA-microT web server v5.0: service integration into miRNA functional analysis workflows. Nucleic Acids Res. 41:W169-W173.
23. Wang, X., and I. M. El Naqa . 2008. Prediction of both conserved and nonconserved microRNA targets in animals. Bioinformatics 24:325-332.
24. Lewis, B. P., C. B. Burge, and D. P. Bartel . 2005. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120:15-20.
25. Kertesz, M., N. Iovino, U. Unnerstall, U. Gaul, and E. Segal . 2007. The role of site accessibility in microRNA target recognition. Nat. Genet. 39:1278-1284.
26. Dweep, H., C. Sticht, P. Pandey, and N. Gretz . 2011. miRWalk-database: prediction of possible miRNA binding sites by "walking" the genes of three genomes. J. Biomed. Inform. 44:839-847.
27. Cline, M. S., M. Smoot, E. Cerami, A. Kuchinsky, N. Landys, C. Workman, et al. 2007. Integration of biological networks and gene expression data using Cytoscape. Nat. Protoc. 2:2366-2382.
28. Bindea, G., B. Mlecnik, H. Hackl, P. Charoentong, M. Tosolini, A. Kirilovsky, et al. 2009. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics 25:1091-1093.
29. Langdon, S. P., S. S. Lawrie, F. G. Hay, M. M. Hawkes, A. McDonald, I. P. Hayward, et al. 1988. Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res. 48:6166-6172.
30. Coller, H. A. 2007. What's taking so long? S-phase entry from quiescence versus proliferation. Nat. Rev. Mol. Cell Biol. 8:667-670.
31. Coppe, J. P., P. Y. Desprez, A. Krtolica, and J. Campisi . 2010. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol. 5:99-118.
32. Lehmann, B. D., M. S. Paine, A. M. Brooks, J. A. McCubrey, R. H. Renegar, R. Wang, et al. 2008. Senescence-associated exosome release from human prostate cancer cells. Cancer Res. 68:7864-7871.
33. Yu, X., S. L. Harris, and A. J. Levine . 2006. The regulation of exosome secretion: a novel function of the p53 protein. Cancer Res. 66:4795-4801.
34. Chen, V. Y., M. M. Posada, L. L. Blazer, T. Zhao, and G. R. Rosania . 2006. The role of the VPS4A-exosome pathway in the intrinsic egress route of a DNA-binding anticancer drug. Pharm. Res. 23:1687-1695.
35. Shedden, K., X. T. Xie, P. Chandaroy, Y. T. Chang, and G. R. Rosania . 2003. Expulsion of small molecules in vesicles shed by cancer cells: association with gene expression and chemosensitivity profiles. Cancer Res. 63:4331-4337.
36. Xu, L., J. Cai, Q. Yang, H. Ding, L. Wu, T. Li, et al. 2013. Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies. J. Cancer Res. Clin. Oncol. 139:1257-1277.
37. Network CGAR. 2011. Integrated genomic analyses of ovarian carcinoma. Nature 474:609-615.
38. Manning, A. L., C. Benes, and N. J. Dyson . 2014. Whole chromosome instability resulting from the synergistic effects of pRB and p53 inactivation. Oncogene 33:2487-2494.
39. McClelland, S. E., R. A. Burrell, and C. Swanton . 2009. Chromosomal instability: a composite phenotype that influences sensitivity to chemotherapy. Cell Cycle 8:3262-3266.
40. Veldman, T., K. T. Etheridge, and C. M. Counter . 2004. Loss of hPot1 function leads to telomere instability and a cut-like phenotype. Curr. Biol. 14:2264-2270.
41. Kadakkuzha, B. M., K. Akhmedov, T. R. Capo, A. C. Carvalloza, M. Fallahi, and S. V. Puthanveettil . 2013. Age-associated bidirectional modulation of gene expression in single identified R15 neuron of Aplysia. BMC Genomics 14:880.
42. Courapied, S., J. Cherier, A. Vigneron, M. B. Troadec, S. Giraud, I. Valo, et al. 2010. Regulation of the Aurora-A gene following topoisomerase I inhibition: implication of the Myc transcription factor. Mol. Cancer. 9:205.
43. Humbert, N., S. Martien, A. Augert, M. Da Costa, S. Mauen, C. Abbadie, et al. 2009. A genetic screen identifies topoisomerase 1 as a regulator of senescence. Cancer Res. 69:4101-4106.
44. Rader, J., M. R. Russell, L. S. Hart, M. S. Nakazawa, L. T. Belcastro, D. Martinez, et al. 2013. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin. Cancer Res. 19:6173-6182.
45. Anders, L., N. Ke, P. Hydbring, Y. J. Choi, H. R. Widlund, J. M. Chick, et al. 2011. A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell 20:620-634.
46. Cruickshanks, H. A., T. McBryan, D. M. Nelson, N. D. Vanderkraats, P. P. Shah, J. van Tuyn, et al. 2013. Senescent cells harbour features of the cancer epigenome. Nat. Cell Biol. 15:1495-1506.
47. Yang, G., D. G. Rosen, Z. Zhang, R. C. Bast Jr., G. B. Mills, J. A. Colacino, et al. 2006. The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc. Natl. Acad. Sci. USA 103:16472-16477.
48. Pinciroli, P., C. Alberti, M. Sensi, S. Canevari, and A. Tomassetti . 2013. An IL6-correlated signature in serous epithelial ovarian cancer associates with growth factor response. BMC Genomics 14:508.